Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Cardioaspirin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aspirin Fails to Cut Cancer Risk in Autoimmune Liver Disease
    Aspirin Fails to Cut Cancer Risk in Autoimmune Liver Disease

    31 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7502909

    FIRSTWORD PHARMA
    31 May 2026
    Share Share
    Plopii Files US Patent For Next-Gen Headache Pill
    Plopii Files US Patent For Next-Gen Headache Pill

    24 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/24/3281031/0/en/biotech-startup-plopii-files-us-patent-on-the-next-generation-headache-pill.html

    GLOBENEWSWIRE
    24 Apr 2026
    Share Share
    Natera Initiates EDEN Study For Early Preeclampsia Risk
    Natera Initiates EDEN Study For Early Preeclampsia Risk

    06 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260206350770/en/Natera-Launches-EDEN-Study-on-Early-Risk-Assessment-for-Preeclampsia-and-Adverse-Pregnancy-Outcomes

    BUSINESSWIRE
    06 Feb 2026
    Share Share
    Aspire Bio Partners Microsize For Sublingual Aspirin Development
    Aspire Bio Partners Microsize For Sublingual Aspirin Development

    29 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-29/aspire-biopharma-secures-agreement-with-microsize-for-development-of-novel-sublingual-aspirin

    PHARMIWEB
    29 Jan 2026
    Share Share
    Aspire Biopharma Secures FDA Pre-IND for Sublingual OTASA
    Aspire Biopharma Secures FDA Pre-IND for Sublingual OTASA

    07 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-07/aspire-biopharma-announces-successful-pre-ind-meeting-with-fda-for-high-dose-sublingual-aspirin-ota

    PHARMIWEB
    07 Jan 2026
    Share Share
    Aspire Bio Seeks FDA Pre-IND Meeting For Sublingual Aspirin
    Aspire Bio Seeks FDA Pre-IND Meeting For Sublingual Aspirin

    02 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-02/aspire-biopharma-submits-pre-ind-meeting-request-and-briefing-package-to-us-fda-for-sublingual-asp

    PHARMIWEB
    02 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.